3 days popular7 days popular1 month popular3 months popular

Corporate Compliance And Transparency In The Pharma Sector, 18-19 October 2012, Prague, Czech Republic

Stricter regulations and various in pharma ensure that the industry is ever-evolving and moving forward. From improving the quality process, reducing costs and remarkable progress in R&D, now is the optimal time to look at the transparency deficiencies in the pharma sector. In which areas do you think increased transparency would be most welcome?

2-DAY conference by Fleming will look at this topic thoroughly.

& TRANSPARENCY IN THE PHARMA SECTOR

18 -19 October 2012, , Czech Republic

17 SPEAKERS from pharma and biotech companies, law firms, audit companies, governmental bodies and institutions, regulatory authorities, and non-profit organizations will gather with a clear purpose – to share their knowledge and give advice in order to improve public trust in the pharmaceutical sector.

13 PRESENTATIONS will introduce to the attendees the main transparency and compliance issues comprising different perspectives. EFPIA will present the industry perspective on the current state of pharmaceutical transparency in Europe, including an overview of European anti-bribery issues and efforts to prevent them, compliance requirements for the upcoming years and their impact on pharma, as well as promoting trust and transparency in . A special insight into the revision of the transparency directive, with the aim of making the pharmaceutical transparency initiative more successful, will be presented by the European Commission.

3 PANEL DISCUSSIONS will dominate the second conference day. With the focus on achieving corporate compliance in the CEE/CIS region, participants will have the opportunity to share their own knowledge and experience with special features of the CEE/CIS compliance environment, latest developments in transparency and compliance legislation in this region, and special drivers in CEE/CIS compliance. Harmonized legislation in the “new” EU member states vs. countries on their way towards harmonization and the most effective anti-corruption measures in the emerging countries of this region will be discussed as well.

1 ROUND-TABLE DISCUSSION dividing the audience into smaller groups will provide attendees with a unique opportunity to discuss the aggregate spend tracking issues of key concern – the impact on interactions of the pharma sector with the healthcare practitioners and the impact on how institutions and regulatory agencies look at the healthcare practitioners employed by them or working on advisory groups.

COUNTLESS NETWORKING OPPORTUNITIES & REASONS TO ATTEND:

  • Understand the current anti-corruption environment in Europe
  • Hear about “compliance requirements” for compliance programs with a focus on their implementation in organizational context
  • Hear from Novo Nordisk Russia about the FAS issue and understand the lessons learned for multinational pharma companies doing business in Russia
  • Understand how to create an effective “tone from middle” strategy
  • Take part in a focused round-table discussion and interactive panel sessions

Did you find your reason to attend? Do not hesitate and join us in Prague. For detailed information please request the agenda http://pharma.flemingeurope.com/corporate-compliance/request-agenda

Source

About

Established in Slovakia, Fleming Europe represents a Pan-European B2B networking channel for specialists to collect & share knowledge. Since 2004, the company has been encouraging decision makers to share their experiences through market leading conferences, trainings and webinars. The annual audience of 10,000 Banking, Defense, Energy, Oil & Gas, Pharma, Telco and Transport peers benefit from insights on industry trends when applying them to their own business practices.

For more information visit http://www.flemingeurope.com